Compare PHAT & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | OCSL |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 1.0B |
| IPO Year | 2019 | 2007 |
| Metric | PHAT | OCSL |
|---|---|---|
| Price | $10.66 | $11.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $19.50 | $13.10 |
| AVG Volume (30 Days) | ★ 986.1K | 832.8K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 14.45% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $92.15 | N/A |
| Revenue Next Year | $59.79 | $0.31 |
| P/E Ratio | ★ N/A | $184.83 |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $10.63 |
| 52 Week High | $18.31 | $15.85 |
| Indicator | PHAT | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 46.68 |
| Support Level | $10.06 | $11.09 |
| Resistance Level | $12.77 | $13.89 |
| Average True Range (ATR) | 0.68 | 0.26 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 33.87 | 68.18 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.